drugset / Trial / NCT03531645
Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma
Phase 2
Active not recruiting
18 enrolled
M.D. Anderson Cancer Center
AstraZeneca · collabEli Lilly and Company · collab
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to learn if fulvestrant and abemaciclib can help to control low-grade serous ovarian cancer. The safety of this drug combination will also be studied. This is an investigational study. Fulvestrant and abemaciclib are both FDA approved and commercially available for the treatment of several types of cancer. Their use in patients with low-grade serous ovarian cancer is investigational. The study doctor can explain how the study drugs are designed to work. Up to 15 participants will be enrolled in this study. All will take part at MD Anderson.
Timeline
- Start
- 2019-08-13
- Primary completion
- 2027-09-30
- Completion
- 2027-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abemaciclib | Small molecule | 150 mg | Oral |
| Subject | Fulvestrant | Small molecule | 500 mg | Other |